Abstract 52P
Background
Anthracycline-based (A) and taxane-based (T) chemotherapy (ChT) are standards of care for triple-negative (TN) or hormone-resistant advanced/metastatic breast cancer (AMBC) in 1st- or 2nd-line ChT. However, the choice of regimen for oncologists and patients is diverse, requiring consideration of not only survival benefit but also quality of life issues. We reported that most patients received eribulin (E) in 1st- or 2nd- line therapy in the Japanese real-world setting at the ESMO 2018 congress. Here, we report updated data regarding ChT sequences and treatment discontinuation.
Methods
We prospectively registered TN AMBC patients and estrogen receptor-positive and HER2-negative AMBC patients who relapsed during or within 6 months after the end of adjuvant endocrine therapy (ET) and were refractory to at least one previous ET. Patterns of ChT and their feasibility were evaluated (ClinicalTrials.gov No. NCT02551263).
Results
Between June 2015 and July 2017, a total of 201 patients were enrolled, 180 of whom were analyzed. The frequent 1st- and 2nd-line ChT sequences were as follows: T followed by E (n=33), oral FU-based therapy (FU) followed by E (n=26), E followed by T (n=21), T followed by FU (n=11), and E followed by FU (n=10). E was administered in 1st- or 2nd-line therapy for 60 patients who did not receive A, and for 35 patients who did not receive T. The main reason the attending physician chose E for patients who did not receive A was “reducing toxicity” in 38.3%, “non-life threatening” in 30.0%, and “patient preference” in 18.3%. Respective ratios in patients who did not receive T were 34.3%, 34.3%, and 20.0%. Patients treated with E or FU in 1st- and 2nd-line ChT had significantly less discontinuation due to adverse events than those with A/T (1st line: p=0.011, 2nd-line: p=0.036). In contrast, there was no statistical difference between E/FU and A/T in 3rd-line ChT (p=1.000).
Conclusions
This study showed that various 1st- and 2nd-sequence treatments including E were chosen in a real-world setting. The lower proportion of adverse events and lower discontinuation rate of E/FU in 1st- and 2nd-line therapy may be due to the better feasibility of these treatments.
Clinical trial identification
NCT02551263.
Editorial acknowledgement
Legal entity responsible for the study
Kyoto Breast Cancer Research Network.
Funding
Eisai Co., Ltd.
Disclosure
T. Kagimura: Research grant/Funding (self): Eisai. T. Taguchi: Honoraria (self), Donation: Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session